Last reviewed · How we verify

NCT05850845

Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN

Status unknown Last updated 9 May 2023
What this trial tests

trial testing Microscopic hyperspectral imaging system in Hyperspectral Imaging in 40 participants. Status unknown.

Timeline
25 June 2023
Primary endpoint
20 July 2023
30 December 2023

Quick facts

Lead sponsorQianfoshan Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date25 June 2023
Primary completion20 July 2023
Estimated completion30 December 2023

Drugs / interventions tested

Conditions studied

Sponsor

Qianfoshan Hospital

Who can join

Adults 18 to 90, any sex, with Hyperspectral Imaging or Idiopathic Membranous Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators propose hyperspectral imaging analysis as a method to distinguish the efficacy of hormone-combined cyclophosphamide therapy for PMN, and classify sensitive and insensitive patients treated with hormone-combined cyclophosphamide regimen. A variety of machine learning models were used to prove that hyperspectral imaging technology could assist patients in selecting the optimal treatment plan, and further explore the predictive indicators of PMN treatment effect.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Microscopic hyperspectral imaging system

Trials testing the same drug.

Other Qianfoshan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05850845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing